Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.
- 1 October 1988
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 85 (20) , 7719-7723
- https://doi.org/10.1073/pnas.85.20.7719
Abstract
Previous studies have demonstrated that bispecific hybrid antibodies produced by cell-cell fusion or chemically conjugated heteroaggregates can direct cytotoxic T lymphocytes to kill target cells for which they have no intrinsic specificity, a phenomenon we call effector cell retargeting (ECR). These studies used bispecific reagents with one specificity directed to CD3 or Ti on the effector cell and the other directed to a target cell antigen. To avoid the need to create different hybrid hybridomas for each target antigen we have developed a universal means to elicit ECR through the use of an antiglobulin step. We have constructed a bispecific hybrid antibody with dual specificity for CD3 and a rat immunoglobulin light chain allotype. This bispecific antibody could mediate ECR to a range of target cells, each coated with distinct surface-binding rat monoclonal antibodies. A particular advantage of targeting to surface-bound monoclonal antibodies is that all other available effector systems may also attack the same antibody-coated target cell.This publication has 26 references indexed in Scilit:
- Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies.The Journal of Experimental Medicine, 1986
- THERAPEUTIC POTENTIAL OF MONOCLONAL ANTIBODIES TO THE LEUKOCYTE-COMMON ANTIGENTransplantation, 1985
- Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibodyNature, 1985
- Hybrid antibodies can target sites for attack by T cellsNature, 1985
- Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.The Journal of Experimental Medicine, 1984
- Hybrid hybridomas and their use in immunohistochemistryNature, 1983
- Segregation of mouse hemopoietic progenitor cells using the monoclonal antibody, YBM/42Journal of Cellular Physiology, 1983
- Biological and Clinical Implications of Lymphocyte Hybridomas: Tumor Therapy with Monoclonal AntibodiesAnnual Review of Medicine, 1983
- Monoclonal Antibodies Specific for Rat IgG1, IgG2a, and IgG2b Subclasses, and Kappa Chain Monotypic and Allotypic Determinants: Reagents for Use with Rat Monoclonal AntibodiesHybridoma, 1982
- Monoclonal antibodies in cell‐mediated cytotoxicity against human melanoma and colorectal carcinomaEuropean Journal of Immunology, 1979